Westchester Capital Management (New York)’s Trillium Therapeutics Inc. TRIL Stock Holding History

Westchester Capital Management (New York)’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,597,153	Closed	-$28M	–	451
2021 Q3	$28M	Buy	+1,597,153	New	+$18.7M	0.81%	24

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Westchester Capital Management (New York)'s TRIL Position: Q4 2021 in Review

Westchester Capital Management (New York) sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,597,153 shares — an estimated $28M sold.

Westchester Capital Management (New York) first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $28M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Westchester Capital Management (New York) reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Westchester Capital Management (New York) sold 1,597,153 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $28M.
Westchester Capital Management (New York) first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Westchester Capital Management (New York)'s Trillium Therapeutics Inc. position peaked at $28M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.